DuPont gets clearance for Definity

DuPont Pharmaceuticals has received Food and Drug Administration clearance for its Definity ultrasound contrast agent. Definity is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, according to the Wilmington, DE-based firm.

Because it's not derived from blood, Definity eliminates the risks associated with the use of blood-based products, according to DuPont. Definity is available through flexible dosing and administration through bolus injection or continuous intravenous infusion. DuPont believes that Definity provides a relatively long window of time for image acquisition. The vendor plans to commercially introduce Definity beginning early this fall.

By AuntMinnie.com staff writers
August 1, 2001

Related Reading

DuPont expands radiopharmaceutical efforts in Puerto Rico, July 31, 2001

DuPont pharma divestiture could cast ripples in imaging, June 22, 2001

Bristol-Myers Squibb to buy DuPont Pharmaceuticals, June 12, 2001

DuPont closes in on fate of medical imaging business, April 9, 2001

Copyright © 2001 AuntMinnie.com

Page 1 of 512
Next Page